Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEU2 | Q9Y3R4 | 5/20 | 0.43 |
| ▸ | NEU3 | Q9UQ49 | 5/20 | 0.43 |
| ▸ | NEU4 | Q8WWR8 | 3/20 | 0.43 |
| ▸ | NEU1 | Q99519 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7829019 | 1.00 | NEU2 (0.43) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL7829023 | 1.00 | NEU2 (0.43) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL7827367 | 0.91 | NEU2 (0.48) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL7827370 | 0.91 | NEU2 (0.48) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL14526696 | 0.90 | NEU2 (0.35) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL23366169 | 0.89 | NEU2 (0.46) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL3677345 | 0.89 | NEU2 (0.55) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL3677348 | 0.89 | NEU2 (0.55) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL126534 | 0.89 | NEU2 (0.55) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL7828982 | 0.86 | MAPT (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054718-A1 | Dimeric compounds and their use as anti-viral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054718-A1 | Dimeric compounds and their use as anti-viral agents | EIF2AK2, IRF3, SARS1 | NEU2 566/4885NEU3 913/4885NEU4 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.